supplementhackr
High T

High G Hardcore Formulation

Serving
2 Capsule(s)
Per container
30
Form
capsule-unknown
DSLD
12467
Formula hash
4d5b54472cfa
Brand context
High T
Catalog
20
products
With avoid flag
20
products
FDA recalls
0
history
CAERS
5
reports
Avoid-flaggedObjective label signals
Flagged excipients
5
1 avoid · 4 caution
FDA recalls
0
no recall history
CAERS reports
5
FDA consumer events
Certifications
0
none recorded
1 avoid-level excipient · Every flag below links to the authority's published citation.

Supplement Facts

4 active ingredients
IngredientAmount% DV
AlphaSize Alpha GPC
Proprietary Blendherb
300 mg—
SerinAid(R)
Phosphatidylserineother
125 mg—
Mucuna pruriens Extract
Cowhageherb
40 mg—
Amino Acid Blend
Blend (Amino Acid/Protein)other
560 mg—
Flagged excipients

5 flagged · authority citations

  • ● AVOIDTitanium Dioxide
    color

    Banned in EU food products effective 2022-08 (Commission Regulation (EU) 2022/63) following EFSA Panel opinion that a safe daily intake could not be established due to genotoxicity concerns. Still GRAS in the US under 21 CFR 73.575 but EU position is stricter.

    eur-lex.europa.eu →efsa.europa.eu →ecfr.gov →
  • ◐ CAUTIONFD&C BLUE #1
    color

    EU requires 'attention in children' warning per Commission Regulation 1333/2008 Annex III. Limited to specific food categories; capsule-shell use permitted with restrictions.

    eur-lex.europa.eu →
  • ◐ CAUTIONFD&C RED #40
    color

    EU requires the same 'attention/activity in children' warning label as Yellow 5 per Commission Regulation 1333/2008 Annex III. California enacted a public-school ban effective 2028 (AB 2316, 2024).

    eur-lex.europa.eu →leginfo.legislature.ca.gov →
  • ◐ CAUTIONFD&C YELLOW #6
    color

    EU requires 'attention in children' warning per Reg 1333/2008 Annex III (Southampton study 2007). Banned in Norway + Finland; allowed in US under 21 CFR 74.706 with declaration.

    eur-lex.europa.eu →
  • ◐ CAUTIONFD&C YELLOW #5
    color

    EU requires warning label 'may have an adverse effect on activity and attention in children' per Commission Regulation 1333/2008 Annex III (following Southampton study 2007). FDA requires specific label declaration (21 CFR 74.705).

    eur-lex.europa.eu →ecfr.gov →
FDA CAERS · adverse event context
5
consumer-submitted adverse event reports filed with the FDA CFSAN Adverse Event Reporting System mentioning this product or its brand.

CAERS reports are unverified consumer submissions — not adjudicated causality. Large well-known brands accumulate proportionally more reports simply due to broader use. About CAERS →

Other ingredients

Di Potassium Phosphate